

# Mary K Crow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6166977/publications.pdf>

Version: 2024-02-01

119  
papers

15,531  
citations

19657

61  
h-index

23533

111  
g-index

123  
all docs

123  
docs citations

123  
times ranked

17254  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2003, 349, 2399-2406.	27.0	1,270
2	Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. <i>Nature Immunology</i> , 2007, 8, 487-496.	14.5	1,210
3	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
4	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
5	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
6	Activation of the interferon- $\beta$ pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. <i>Arthritis and Rheumatism</i> , 2005, 52, 1491-1503.	6.7	608
7	Identification of a central role for complement in osteoarthritis. <i>Nature Medicine</i> , 2011, 17, 1674-1679.	30.7	470
8	Type I Interferon in the Pathogenesis of Lupus. <i>Journal of Immunology</i> , 2014, 192, 5459-5468.	0.8	439
9	Coordinate overexpression of interferon- $\beta$ -induced genes in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3958-3967.	6.7	394
10	Interferon target-gene expression and epigenomic signatures in health and disease. <i>Nature Immunology</i> , 2019, 20, 1574-1583.	14.5	316
11	Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. <i>Arthritis and Rheumatism</i> , 2006, 54, 1906-1916.	6.7	293
12	Arterial Stiffness in Chronic Inflammatory Diseases. <i>Hypertension</i> , 2005, 46, 194-199.	2.7	269
13	Microarray Analysis of Interferon-regulated Genes in SLE. <i>Autoimmunity</i> , 2003, 36, 481-490.	2.6	251
14	Association of the IRF5 risk haplotype with high serum interferon- $\beta$ activity in systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 2481-2487.	6.7	246
15	Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 249.	3.9	241
16	Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. <i>Current Opinion in Rheumatology</i> , 2008, 20, 565-572.	4.3	231
17	Activation of Mammalian Target of Rapamycin Controls the Loss of TCR $\beta$ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation. <i>Journal of Immunology</i> , 2009, 182, 2063-2073.	0.8	221
18	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. <i>Journal of Autoimmunity</i> , 2015, 63, 47-58.	6.5	215

#	ARTICLE	IF	CITATIONS
19	Synovial inflammation in patients undergoing arthroscopic meniscectomy: Molecular characterization and relationship to symptoms. <i>Arthritis and Rheumatism</i> , 2011, 63, 391-400.	6.7	213
20	Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN- $\gamma$ in Lupus Patients In Vivo. <i>Journal of Immunology</i> , 2009, 182, 34-38.	0.8	210
21	Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. <i>Journal of Leukocyte Biology</i> , 1995, 58, 209-216.	3.3	203
22	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	187
23	Type I Interferons in Autoimmune Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 369-393.	22.4	179
24	Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 3412-3419.	6.7	169
25	Microarray analysis of gene expression in lupus. <i>Arthritis Research</i> , 2003, 5, 279.	2.0	167
26	Activation of the type I interferon pathway in primary Sjogren's syndrome. <i>Journal of Autoimmunity</i> , 2010, 35, 225-231.	6.5	165
27	Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1003-1009.	0.9	154
28	Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. <i>Arthritis and Rheumatism</i> , 1999, 42, 871-881.	6.7	150
29	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 2686-2696.	5.6	149
30	A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. <i>Arthritis and Rheumatism</i> , 1991, 34, 468-480.	6.7	145
31	Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN- $\gamma$ and Serologic Autoimmunity in Lupus Patients. <i>Journal of Immunology</i> , 2011, 187, 1298-1303.	0.8	143
32	Augmented interferon- $\gamma$ pathway activation in patients with Sjogren's syndrome treated with etanercept. <i>Arthritis and Rheumatism</i> , 2007, 56, 3995-4004.	6.7	140
33	IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 463-469.	0.9	127
34	Reactive oxygen species induce virus-independent MAVS oligomerization in systemic lupus erythematosus. <i>Science Signaling</i> , 2016, 9, ra115.	3.6	127
35	Proteomic Analysis of Synovial Fluid From the Osteoarthritic Knee: Comparison With Transcriptome Analyses of Joint Tissues. <i>Arthritis and Rheumatism</i> , 2013, 65, 981-992.	6.7	126
36	Interferon- $\gamma$ in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2004, 16, 541-547.	4.3	124

#	ARTICLE	IF	CITATIONS
37	Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 3607-3614.	6.7	123
38	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2006, 26, 165-171.	6.5	122
39	Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. <i>Arthritis and Rheumatism</i> , 2012, 64, 982-992.	6.7	121
40	Type I interferon in organ-targeted autoimmune and inflammatory diseases. <i>Arthritis Research and Therapy</i> , 2010, 12, S5.	3.5	111
41	Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R151.	3.5	103
42	Advances in understanding the role of type I interferons in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2014, 26, 467-474.	4.3	97
43	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. <i>Arthritis and Rheumatology</i> , 2020, 72, 1990-1997.	5.6	96
44	Targeting of type I interferon in systemic autoimmune diseases. <i>Translational Research</i> , 2015, 165, 296-305.	5.0	95
45	Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. <i>Arthritis and Rheumatism</i> , 2009, 60, 22-29.	6.7	93
46	Degos Disease. <i>American Journal of Clinical Pathology</i> , 2011, 135, 599-610.	0.7	91
47	A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. <i>EMBO Molecular Medicine</i> , 2011, 3, 142-152.	6.9	91
48	Type I interferons in host defence and inflammatory diseases. <i>Lupus Science and Medicine</i> , 2019, 6, e000336.	2.7	91
49	Interferon- $\gamma$ : A new target for therapy in systemic lupus erythematosus?. <i>Arthritis and Rheumatism</i> , 2003, 48, 2396-2401.	6.7	86
50	Collaboration, Genetic Associations, and Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2008, 358, 956-961.	27.0	86
51	Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 541-546.	6.7	84
52	Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to Toll-like receptor 4 and Toll-like receptor 2 ligands via soluble CD14. <i>Arthritis and Rheumatism</i> , 2012, 64, 2268-2277.	6.7	83
53	Nilotinib (Tasigna, $\text{C}$ ) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 213.	3.5	83
54	The <i>PTPN22</i> C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon- $\gamma$ activity and low tumor necrosis factor $\beta$ levels in patients with lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 2818-2823.	6.7	82

#	ARTICLE	IF	CITATIONS
55	Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon $\beta$ / $\alpha$ ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort. <i>Arthritis and Rheumatism</i> , 2010, 62, 392-401.	6.7	77
56	Long interspersed nuclear elements (LINE-1): Potential triggers of systemic autoimmune disease. <i>Autoimmunity</i> , 2010, 43, 7-16.	2.6	76
57	Age- and sex-related patterns of serum interferon $\alpha$ activity in lupus families. <i>Arthritis and Rheumatism</i> , 2008, 58, 2113-2119.	6.7	74
58	Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN $\beta$ : A Potential Role in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 177, 383-394.	0.8	70
59	Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass. <i>Circulation</i> , 2007, 116, 419-426.	1.6	69
60	Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1018-1024.	4.1	68
61	Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. <i>Journal of Autoimmunity</i> , 2018, 88, 75-82.	6.5	65
62	Interferon $\alpha$ and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. <i>Arthritis and Rheumatology</i> , 2015, 67, 977-987.	5.6	64
63	Induction of Fas Ligand-Mediated Apoptosis by Interferon $\beta$ . <i>Clinical Immunology</i> , 2000, 95, 218-226.	3.2	59
64	Interferon-alpha: A Therapeutic Target in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 173-186.	1.9	59
65	Regulation of CD40 ligand expression in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2001, 13, 361-369.	4.3	56
66	Increased IFN $\beta$ activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits. <i>Journal of Neuroimmunology</i> , 2013, 255, 85-91.	2.3	54
67	Interferon pathway activation in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2005, 7, 463-468.	4.7	48
68	T Cell Proliferation Induced by Autologous Non-T Cells Is a Response to Apoptotic Cells Processed by Dendritic Cells. <i>Journal of Immunology</i> , 2002, 169, 1241-1250.	0.8	44
69	Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 206-212.	3.4	37
70	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
71	Developments in the clinical understanding of lupus. <i>Arthritis Research and Therapy</i> , 2009, 11, 245.	3.5	36
72	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
74	Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. <i>Human Immunology</i> , 2001, 62, 1346-1355.	2.4	32
75	Modification of accessory molecule signaling. <i>Seminars in Immunopathology</i> , 2006, 27, 409-424.	4.0	31
76	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. <i>Scientific Reports</i> , 2017, 7, 7354.	3.3	28
77	Interferon $\gamma$ or $\beta$ : which is the culprit in autoimmune disease?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 439-440.	8.0	27
78	Activated B lymphocytes: Stimulators of an augmented autologous mixed leukocyte reaction. <i>Cellular Immunology</i> , 1985, 90, 555-568.	3.0	26
79	Costimulatory molecules and T-cell-B-cell interactions. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 175-191.	1.9	26
80	Early Growth Response-1 Is Required for CD154 Transcription. <i>Journal of Immunology</i> , 2006, 176, 811-818.	0.8	26
81	New Pieces to the SLE Cytokine Puzzle. <i>Clinical Immunology</i> , 1999, 91, 1-5.	3.2	23
82	SLE: reconciling heterogeneity. <i>Lupus Science and Medicine</i> , 2019, 6, e000280.	2.7	23
83	Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2016, 172, 34-43.	3.2	19
84	TREX1 variants in Sjogren's syndrome related lymphomagenesis. <i>Cytokine</i> , 2020, 132, 154781.	3.2	18
85	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. <i>Frontiers in Immunology</i> , 2013, 4, 238.	4.8	17
86	Activation of type I interferon in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 579-588.	3.0	16
87	Introduction Type I Interferon and Autoimmune Disease. <i>Autoimmunity</i> , 2003, 36, 445-446.	2.6	14
88	Mitochondrial DNA promotes autoimmunity. <i>Science</i> , 2019, 366, 1445-1446.	12.6	14
89	Soluble Mediators as Therapeutic Targets in Systemic Lupus Erythematosus: Cytokines, Immunoglobulin Receptors, and the Complement System. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 103-119.	1.9	13
90	Ongoing Immunoglobulin Class Switch DNA Recombination in Lupus B Cells: Analysis of Switch Regulatory Regions. <i>Autoimmunity</i> , 2004, 37, 431-443.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Interferon-induced versus chemokine transcripts as lupus biomarkers. <i>Arthritis Research and Therapy</i> , 2008, 10, 126.	3.5	12
92	CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus. <i>Lancet</i> , The, 2018, 391, 1126-1127.	13.7	11
93	Measurement of Cytokines in Autoimmune Disease. , 2004, 102, 129-154.		10
94	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. <i>Clinical Immunology</i> , 2021, 223, 108649.	3.2	9
95	Etiology and Pathogenesis of Systemic Lupus Erythematosus. , 2017, , 1329-1344.		7
96	Reactivity of IgG With the p40 Protein Encoded by the Long Interspersed Nuclear Element 1 Retroelement: Comment on the Article by Carter et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 374-376.	5.6	5
97	A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis?. <i>Arthritis Care and Research</i> , 2011, 63, 766-774.	3.4	4
98	Pregnancy and Rheumatic Disease: Experience at a Single Center in New York City During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2021, 73, 1004-1012.	3.4	4
99	The role of immunomodulatory medications in the treatment of COVID-19. <i>Current Opinion in Rheumatology</i> , 2021, 33, 431-445.	4.3	4
100	Measuring Interferon Alpha and Other Cytokines in SLE. <i>Methods in Molecular Biology</i> , 2014, 1134, 131-150.	0.9	4
101	Charles L Christian: model physician scientist and mentor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 685-688.	0.9	3
102	Etiology and Pathogenesis of Systemic Lupus Erythematosus. , 2013, , 1269-1282.		3
103	Hydroxychloroquine and lupus flare: a good drug, but we need to do better. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2021-221590.	0.9	3
104	When a Diagnosis Has No Name: Uncertainty and Opportunity. <i>ACR Open Rheumatology</i> , 2022, 4, 197-201.	2.1	3
105	Mentors and heroes: The foundation and future of rheumatology. <i>Arthritis and Rheumatism</i> , 2007, 56, 1037-1043.	6.7	2
106	Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: Clues to disease pathogenesis. <i>Current Rheumatology Reports</i> , 2008, 10, 165-167.	4.7	2
107	Cytokines in Lupus. , 2019, , 137-152.		2
108	Preclinical Dose-Escalation Study of ZSJ-0228, a Polymeric Dexamethasone Prodrug, in the Treatment of Murine Lupus Nephritis. <i>Molecular Pharmaceutics</i> , 2021, 18, 4188-4197.	4.6	2

#	ARTICLE	IF	CITATIONS
109	Academic rheumatology: Not just a man's world. <i>Arthritis and Rheumatism</i> , 2005, 52, 694-696.	6.7	1
110	Fast forward for systemic lupus erythematosus clinical trials. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 387-387.	3.2	1
111	Cytokines and Interferons in Lupus. , 2013, , 62-75.		1
112	Georgia Abortion Law and Our Commitment to Patients. <i>Arthritis and Rheumatology</i> , 2020, 72, 377-378.	5.6	1
113	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 549-550.	5.6	1
114	Identification of Candidate Predictors of Lupus Flare. <i>Transactions of the American Clinical and Climatological Association</i> , 2015, 126, 184-96.	0.5	1
115	Clinical applications of IFN- $\beta$ blockade in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 617-619.	0.3	0
116	Interferon-Alpha in Systemic Lupus Erythematosus. , 2011, , 307-320.		0
117	Soluble CD14 in synovial fluid from patients with OA and meniscal injury modulates the response of synovial fibroblasts to LPS. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A34-A35.	0.9	0
118	Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN. <i>Journal of Pediatric Infectious Diseases</i> , 2017, 12, 176-183.	0.2	0
119	07.08â€¦Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0